Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.

Biotechnology

Olema Oncology

Sean P. Bohen

Kristin Lowland Lanzi

Peter Kushner

Geoffrey Mogilner

Sasha Austin

Kamesh Kuchimanchi

Jim Zhang

Kristin Lanzi

David C. Myles

Naseem Zojwalla

Julie Dexter

Shane Kovacs

The Clinical Development Team at Olema Oncology is responsible for the strategic planning, execution, and management of clinical trials, including the ongoing Phase 1/2 trial of OP-1250. This team ensures the rigorous design and implementation of clinical studies while maintaining compliance with regulatory standards. Their collective efforts aim to advance OP-1250 through the clinical development pipeline, ultimately contributing to the availability of innovative therapies for women's cancers.

Clinical Development Team

Leadership Team

Clinical and Pharmacology

Clinical Development Team

About

Team members

Other teams at Olema Oncology

Leadership Team

Clinical and Pharmacology